Sept 16 (Reuters) - CSL Ltd CSL.AX:
CSL PARTNERS ON NEW COAGULATION TREATMENT
ENTERED INTO AN AGREEMENT WITH PRIVATELY HELD DUTCH BIOTECH COMPANY, VARMX BV
AGREEMENT TO DEVELOP A NEW TREATMENT TO RESTORE BLOOD COAGULATION IN PATIENTS TAKING A FXA INHIBITOR
WILL MAKE AN UPFRONT PAYMENT TO VARMX OF US$117 MILLION FOR AN EXCLUSIVE OPTION TO ACQUIRE COMPANY
VARMX WILL RECEIVE PAYMENTS OF UP TO US$388 MILLION UP TO LAUNCH OF VMX-C001, PLUS FURTHER COMMERCIAL MILESTONES THEREAFTER
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))